Elanco Animal Health, Inc. (ELAN)

Over the past six months, Elanco Animal Health's stock price has seen a positive trend, with a 9.56% increase as of May 6, 2026, and shares have risen approximately 163% over the past year. Key events impacting the stock include strong Q1 2026 results with revenue increasing 15% year-over-year, raised full-year 2026 revenue estimate and adjusted EPS guidance, strong performance of new products like Zenrelia and Credelio Quattro, a restructuring plan aimed at margin expansion and optimizing its footprint, and the acquisition of the AHV farm animal business.

Demand for Elanco Animal Health's products and services can be subject to seasonality, influenced by weather conditions and varying environmental patterns, leading to regional and seasonal fluctuations in the company's operational results. Parasiticides for pets experience higher demand in the first half of the year. Seasonal climate shifts can impact conditions in poultry houses, leading to fluctuations in the risk of diseases.

Elanco Animal Health, Inc. operates in the Healthcare sector, focusing on animal health within the Pharmaceuticals and Biotechnology industry. The company offers a range of products for preventing and treating diseases in farm animals and pets. Major pet health products include parasiticides, vaccines, and therapeutics, with key brands like Seresto and Credelio. For farm animals, Elanco provides medicated feed additives, antibiotics, vaccines, and insecticides for cattle, poultry, swine, and sheep. Elanco is recognized as the third-largest animal health company globally.

Elanco Animal Health has a significant global presence, supplying products and services to customers in over 90 countries. In 2025, 47% of its revenue came from the U.S., while international markets accounted for 53%. The company's global headquarters is in Indianapolis, Indiana, U.S. Elanco is consolidating its global operations, including plans to close its German animal health R&D facility and increase investment in U.S.-based innovation and manufacturing.

Elanco maintains a strong reputation as a global leader in animal health, being the third-largest company in the sector. The company emphasizes its commitment to improving the health of animals, people, and the planet, fostering a cause-driven culture. Elanco's reputation has been positively influenced by its strong financial performance and innovation, including the successful launch and market penetration of new products. The company's strategic shift to focus on high-value pet health and livestock sustainability initiatives also reflects a proactive approach to its business model.

Elanco Animal Health's ownership is primarily held by institutional investors, who collectively hold a significant majority of the company's stock, estimated to be around 75.51% to 91.6%. Major institutional owners include Dodge & Cox, Fmr Llc, Vanguard Group Inc, and BlackRock, Inc. Individual investors and company insiders hold smaller percentages of the stock.